Parenteral immunization of mice with a genetically inactivated pertussis toxin DNA vaccine induces cell-mediated immunity and protection

Journal of Medical Microbiology

Volumn 57, Issue 1, 2008, Pages 28-35

  Fry, Scott R ^a,b   Chen, Austen Y ^a   Daggard, Grant ^a   Mukkur, Trilochan K S ^a  

^a UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^b Panbio Limited   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VACCINE; INTERLEUKIN 2; PERTUSSIS VACCINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CHO CELL; CONTROLLED STUDY; DISEASE MODEL; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERTUSSIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; SPLEEN CELL; SUPERNATANT; TH1 CELL; TH2 CELL; VACCINATION;

ANIMALS; ANTIBODY FORMATION; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON TYPE II; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; PERTUSSIS TOXIN; PERTUSSIS VACCINE; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, DNA; VACCINES, INACTIVATED; WHOOPING COUGH;

EID: 38349026266     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.47527-0     Document Type: Article

References (48)

1. Barlow, W. E., Davis, R. L., Glasser, J. W., Rhodes, P. H., Thompson, R. S., Mullooly, J. P., Black, S. B., Shinefield, H. R., Ward, J. I. & other authors (2001). The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 345, 656-661.
2. Barnard, A., Mahon, B. P., Watkins, J., Redhead, K. & Mills, K. H. (1996). Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. Immunology 87, 372-380.
3. Barry, E. M., Gomez-Duarte, O., Chatfield, S., Rappuoli, R., Pizza, M., Losonsky, G., Galen, J. & Levine, M. M. (1996). Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infect Immun 64, 4172-4181.
4. Boucher, P., Sato, H., Sato, Y. & Locht, C. (1994). Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein. Infect Immun 62, 449-456.
5. Castro, M. G., McNamara, U. & Carbonetti, N. H. (2001). Expression, activity and cytotoxicity of pertussis toxin S1 subunit in transfected mammalian cells. Cell Microbiol 3, 45-54.
6. Chen, A. Y., Fry, S. R., Forbes-Faulkner, J., Daggard, G. E. & Mukkur, T. K. (2006). Comparative immunogenicity of M. hyopneumoniae NrdF encoded in different expression systems delivered orally via attenuated S. typhimurium aroA in mice. Vet Microbiol 114, 252-259.
7. Cherry, J. D., Grimprel, E., Guiso, N., Heininger, U. & Mertsola, J. (2005). Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J 24 (Suppl.), S25-S34.
8. De Magistris, M. T., Romano, M., Nuti, S., Rappuoli, R. & Tagliabue, A. (1988). Dissecting human T cell responses against Bordetella species. J Exp Med 168, 1351-1362.
9. Delogu, G., Howard, A., Collins, F. M. & Morris, S. L. (2000). DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 68, 3097-3102.
10. Donnelly, J. J., Ulmer, J. B., Shiver, J. W. & Liu, M. A. (1997). DNA vaccines. Annu Rev Immunol 15, 617-648.
11. Donnelly, S., Loscher, C. E., Lynch, M. A. & Mills, K. H. (2001). Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1β in a new murine model for analysis of neuronal side effects of vaccination. Infect Immun 69, 4217-4223.
12. Gold, M. S., Noonan, S., Osbourn, M., Precepa, S. & Kempe, A. E. (2003). Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. Med J Aust 179, 191-194.
13. Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi, A. E., Anemona, A., Ciofi degli Atti, M. L., Giammanco, A., Panei, P. & other authors (1996). A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 334, 341-349.
14. Gurunathan, S., Klinman, D. M. & Seder, R. A. (2000). DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18, 927-974.
15. Gustafsson, L., Hallander, H. O., Olin, P., Reizenstein, E. & Storsaeter, J. (1996). A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334, 349-355.
16. Halperin, S. A., Issekutz, T. B. & Kasina, A. (1991). Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin. J Infect Dis 163, 355-361.
17. Imaizumi, A., Suzuki, Y., Ono, S., Sato, H. & Sato, Y. (1983). Heptakis(2,6-O-dimethyl) β-cyclodextrin: a novel growth stimulant for Bordetella pertussis phase I. J Clin Microbiol 17, 781-786.
18. Kamachi, K. & Arakawa, Y. (2004). Expression of a C terminally truncated form of pertussis toxin S1 subunit effectively induces protection against pertussis toxin following DNA-based immunization. Infect Immun 72, 4293-4296.
19. Kamachi, K. & Arakawa, Y. (2007). Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit. Vaccine 25, 1000-1006.
20. Kamachi, K., Konda, T. & Arakawa, Y. (2003). DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice. Vaccine 21, 4609-4615.
21. Klinman, D. M., Yamshchikov, G. & Ishigatsubo, Y. (1997). Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158, 3635-3639.
22. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
23. Lee, S. F., March, R. J., Halperin, S. A., Faulkner, G. & Gao, L. (1999). Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii. Infect Immun 67, 1511-1516.
24. Lee, S. F., Halperin, S. A., Salloum, D. F., MacMillan, A. & Morris, A. (2003). Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein. Infect Immun 71, 2272-2275.
25. Mahon, B. P., Ryan, M. S., Griffin, F. & Mills, K. H. (1996). Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect Immun 64, 5295-5301.
26. McGuirk, P. & Mills, K. H. G. (2000). A regulatory role for interleukin 4 in differential inflammatory response in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines. Infect Immun 68, 1383-1390.
27. Mills, K. H. (2001). Immunity to Bordetella pertussis. Microbes Infect 3, 655-677.
28. Mills, K. H., Barnard, A., Watkins, J. & Redhead, K. (1993). Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 61, 399-410.
29. Mills, K. H., Ryan, M., Ryan, E. & Mahon, B. P. (1998). A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 66, 594-602.
30. Nascimento, I. P., Dias, W. O., Mazzantini, R. P., Miyaji, E. N., Gamberini, M., Quintilio, W., Gebara, V. C., Cardoso, D. F., Ho, P. L. & other authors (2000). Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice. Infect Immun 68, 4877-4883.
31. Nencioni, L., Pizza, M., Bugnoli, M., De Magistris, T., Di Tommaso, A., Giovannoni, F., Manetti, R., Marsili, I., Matteucci, G. & other authors (1990). Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun 58, 1308-1315.
32. Olin, P., Rasmussen, F., Gustafsson, L., Hallander, H. O., Heijbel, H. & for the Ad Hoc Group for the Study of Pertussis Vaccines (1997). Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350, 1569-1577.
33. Pizza, M., Covacci, A., Bartoloni, A., Perugini, M., Nencioni, L., De Magistris, M. T., Villa, L., Nucci, D., Manetti, R. & other authors (1989). Mutants of pertussis toxin suitable for vaccine development. Science 246, 497-500.
34. Redhead, K., Watkins, J., Barnard, A. & Mills, K. H. (1993). Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 61, 3190-3198.
35. Rennels, M. B., Deloria, M. A., Pichichero, M. E., Losonsky, G. A., Englund, J. A., Meade, B. D., Anderson, E. L., Steinhoff, M. C. & Edwards, K. M. (2000). Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105, e12.
36. Rowe, J., Yerkovich, S. T., Richmond, P., Suriyaarachchi, D., Fisher, E., Feddema, L., Loh, R., Sly, P. D. & Holt, P. G. (2005). Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect Immun 73, 8130-8135.
37. Sato, Y., Kimura, M. & Fukumi, H. (1984). Development of a pertussis component vaccine in Japan. Lancet 1, 122-126.
38. Sato, H., Sato, Y. * Ohishi, I. (1991). Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies. Infect Immun 59, 3832-3835.
39. Schneerson, R., Robbins, J. B., Taranger, J., Lagergard, T. & Trollfors, B. (1996). A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet 348, 1289-1292.
40. Stainer, D. W. & Scholte, M. J. (1970). A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol 63, 211-220.
41. Tamura, M., Nogimori, K., Murai, S., Yajima, M., Ito, K., Katada, T., Ui, M. & Ishii, S. (1982). Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 21, 5516-5522.
42. Tan, T., Trindade, E. & Skowronski, D. (2005). Epidemiology of pertussis. Pediatr Infect Dis J 24 (Suppl.), S10-S18.
43. Ulmer, J. B., Donnelly, J. J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M. & other authors (1993). Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749.
44. van den Berg, B. M., David, S., Beekhuizen, H., Mooi, F. R. & van Furth, R. (2000). Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens. Vaccine 19, 1118-1128.
45. Vanderzanden, L., Bray, M., Fuller, D., Roberts, T., Custer, D., Spik, K., Jahrling, P., Huggins, J., Schmaljohn, A. & Schmaljohn, C. (1998). DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 246, 134-144.
46. Walker, M. J., Rohde, M., Timmis, K. N. & Guzman, C. A. (1992). Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit. Infect Immun 60, 4260-4268.
47. Wang, R., Doolan, D. L., Le, T. P., Hedstrom, R. C., Coonan, K. M., Charoenvit, Y., Jones, T. R., Hobart, P., Margalith, M. & other authors (1998). Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476-480.
48. Xing, D. K., Das, R. G., Williams, L., Canthaboo, C., Tremmil, J. & Corbel, M. J. (1999). An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines. Vaccine 17, 565-576.